Jaz­z's $1B SCLC drug fails com­bo tri­al, quash­ing hopes of quick full ap­proval. But how much does it mat­ter?

Lur­binecte­din was look­ing like a great turn­around sto­ry for Span­ish biotech Phar­ma­Mar. More than a year af­ter the drug flopped in a Phase III ovar­i­an can­cer study, it hit the mark for over­all re­sponse rate in small cell lung can­cer, at­tract­ed Jazz Phar­ma to gam­ble on a $1 bil­lion pact and land­ed an ac­cel­er­at­ed ap­proval ear­li­er this year.

Un­til it failed the over­all sur­vival end­point in a new Phase III study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER